IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2025

Aggregated presentation by day and by market

Statement of transactions in own shares from June 2nd to June 6th 2025

Name of the issuer	Identity code of the issuer (Legal Entity Identifier)	Day of the transaction	Identity code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
IPSEN	549300M6SGDPB4Z94P11	02/06/2025	FR0010259150	294	102,63197	AQEU
IPSEN	549300M6SGDPB4Z94P11	02/06/2025	FR0010259150	929	102,90904	CCXE
IPSEN	549300M6SGDPB4Z94P11	02/06/2025	FR0010259150	288	102,59167	TQEX
IPSEN	549300M6SGDPB4Z94P11	02/06/2025	FR0010259150	3 069	103,02822	XPAR
IPSEN	549300M6SGDPB4Z94P11	03/06/2025	FR0010259150	294	103,98571	AQEU
IPSEN	549300M6SGDPB4Z94P11	03/06/2025	FR0010259150	929	104,26491	CCXE
IPSEN	549300M6SGDPB4Z94P11	03/06/2025	FR0010259150	288	104,0691	TQEX
IPSEN	549300M6SGDPB4Z94P11	03/06/2025	FR0010259150	2 427	103,81108	XPAR
IPSEN	549300M6SGDPB4Z94P11	04/06/2025	FR0010259150	504	103,79246	AQEU
IPSEN	549300M6SGDPB4Z94P11	04/06/2025	FR0010259150	1 186	103,48668	CCXE
IPSEN	549300M6SGDPB4Z94P11	04/06/2025	FR0010259150	354	103,62825	TQEX
IPSEN	549300M6SGDPB4Z94P11	04/06/2025	FR0010259150	3 306	103,68297	XPAR
IPSEN	549300M6SGDPB4Z94P11	05/06/2025	FR0010259150	300	104,26667	AQEU
IPSEN	549300M6SGDPB4Z94P11	05/06/2025	FR0010259150	750	104,04667	CCXE
IPSEN	549300M6SGDPB4Z94P11	05/06/2025	FR0010259150	250	103,94	TQEX
IPSEN	549300M6SGDPB4Z94P11	05/06/2025	FR0010259150	2 794	104,08021	XPAR
IPSEN	549300M6SGDPB4Z94P11	06/06/2025	FR0010259150	200	103,82	AQEU
IPSEN	549300M6SGDPB4Z94P11	06/06/2025	FR0010259150	400	103,825	CCXE
IPSEN	549300M6SGDPB4Z94P11	06/06/2025	FR0010259150	200	103,875	TQEX
IPSEN	549300M6SGDPB4Z94P11	06/06/2025	FR0010259150	4 250	103,90626	XPAR
			TOTAL	23 012	103,6915

Attachment

EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 23_2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2025

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Scatec signs PPA for 900MW onshore wind project in Egypt

Topics

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Scatec signs PPA for 900MW onshore wind project in Egypt

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Related Articles

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Scatec signs PPA for 900MW onshore wind project in Egypt

Company

Headlines

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Newsletter